

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 16, 2022

EyePoint Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

000-51122
(Commission File Number)

26-2774444
(IRS Employer
Identification No.)

480 Pleasant Street
Watertown, Massachusetts
(Address of Principal Executive Offices)

02472
(Zip Code)

Registrant's Telephone Number, Including Area Code: (617) 926-5000

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001	EYPT	The NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Events.

On November 16, 2022, EyePoint Pharmaceuticals, Inc. posted an updated investor presentation on its website at www.eyepointpharma.com. A copy of the presentation is filed herewith as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.**(d) Exhibits.**

<u>Exhibit No.</u>	<u>Description</u>
99.1	Investor Presentation of EyePoint Pharmaceuticals, Inc. dated November 16, 2022
104	Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EYEPOINT PHARMACEUTICALS, INC.

Date: November 16, 2022

By: /s/ George O. Elston
George O. Elston
Chief Financial Officer



EYEPOINT[®]
PHARMACEUTICALS

Investor Presentation

November 2022

Forward-Looking Statements

Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about our expectations regarding the potential benefits of our partnerships and strategic alliances with other companies, as well as the timing and clinical development of our product candidates, including EYP-1901; the potential for EYP-1901 as a sustained delivery treatment for wet age-related macular degeneration and non-proliferative diabetic retinopathy; and our longer term financial and business goals and expectations, are forward-looking statements. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements are risks and uncertainties inherent in our business including, without limitation: the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; the extent to which COVID-19 impacts our business; our ability to achieve profitable operations and access to needed capital; fluctuations in our operating results; our ability to successfully produce sufficient commercial quantities of YUTIQ® and DEXYCU®; **the loss of pass-through reimbursement status for DEXYCU at the end of 2022; the success of current and future license agreements, including our agreements with Ocumension Therapeutics, Equinox Science and Betta Pharmaceuticals; termination or breach of current license agreements; our dependence on contract research organizations, co-promotion partners, and other outside vendors and service providers; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of our stock price; possible dilution; absence of dividends; and other factors described in our filings with the Securities and Exchange Commission.** We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

COMPANY OVERVIEW

Compelling Pipeline Leverages Proven Durasert® IVT Drug Delivery Technology

EYP-1901 in Phase 2 clinical trials

- Bioerodible Durasert® delivering vorolanib as single injection sustained delivery intravitreal (IVT) insert
 - DAVIO 2 - potential 6-month treatment for wet AMD
 - PAVIA - potential 9-month treatment for non-proliferative diabetic retinopathy (NPDR)

Durasert® - proven IVT drug delivery

- Sustained ocular drug delivery
- Constant (zero-order kinetics) stable release of drug
- Safely administered to over 80,000 patient eyes across four FDA approved products

Strong Balance Sheet

- \$157 million of cash and investments on September 30, 2022
- Cash runway into 2H 2024
- Commercial franchise on target for 2022 break-even

3 | INVESTOR PRESENTATION

 **EYEPOINT**
PHARMACEUTICALS

TECHNOLOGY

DURASERT®



Safe Sustained Intravitreal Drug Delivery

Used in four of six FDA approved intravitreal sustained delivery products

Delivered by a single in-office IVT injection

Continuous, stable release of drug

Non-Erodible Products


- YUTIQ® (EyePoint)
- ILUVIEN® (Alimera)
- RETISERT® (B&L)
- VITRASERT® (B&L)

Bioerodible: EYP-1901

- No polyimide coating
- Initial drug burst from insert surface
- Constant, zero-order kinetic release over months

EYP-1901 utilizes a bioerodible formulation of Durasert for repeated IVT injections

- Sustained, zero-order kinetics drug release over 6-9 months in bioerodible formulation
- High drug load per insert
- Single insert is ~1/5,000 the volume of the vitreous



WHY VOROLANIB?

Vorolanib binds receptors of all VEGF growth factors

Vorolanib selected after evaluation of over 100 tyrosine kinase inhibitors (TKIs)

- Intracellular binding of all vascular endothelial growth factor (VEGF) receptors
- Differentiated mechanism of action versus anti-VEGF biologics
- In-vivo studies demonstrate encouraging neuroprotection data
- Phase 1 and Phase 2 clinical trials as an oral therapy showed compelling efficacy data with no ocular toxicity observed^{1,2}
- Reduced off-target binding of receptors associated with TKI systemic side effects


1. Jackson et al. JAMA Ophthalmol. 2017.
2. Cohen MN et al. Br J Ophthalmol. 2021

6 | INVESTOR ORIENTATION

 EYEPOINT
PHARMACEUTICALS

Vorolanib binds receptors of all VEGF growth factors with strong affinity to VEGF receptor 2 - a receptor associated with blood vessel leakage

VEGF SIGNALING PATHWAYS




VOROLANIB INHIBITS VEGFR

- Binds to the intracellular domain of tyrosine kinases
- Targets the angiogenic VEGF receptors R1, R2 and R3 with high potency

EYP-1901 delivers VEGF receptor binding vorolanib in Bioerodible Durasert®

EYP-1901 IS ~1/5000
OF VITREOUS



EYP-1901

- A single IVT injection of up to 3 inserts
- Bioerodible formulation of Durasert
- Initial drug burst from surface of insert to rapidly reach therapeutic levels in ocular tissues
- Zero order kinetics release expected to provide consistent drug levels through treatment course

Vorolanib

- Binds receptors of all VEGF growth factors
- Different mechanism of action from ligand blocking anti-VEGF biologics

EYP-1901

PHASE 1 DAVIO CLINICAL TRIAL 12 MONTH RESULTS

EYP-1901 Phase 1 DAVIO clinical trial enrolled 17 patients over four different dosages

Primary Endpoint: Safety

- Ocular and non-ocular TEAEs through month-12

Secondary Endpoints

- Supplemental anti-VEGF therapy through 6-months
- Change in BCVA from baseline
- CST as measured by OCT



EYP-1901 Phase 1 DAVIO clinical trial demonstrated favorable overall safety data at 12-months meeting primary endpoint

Ocular AEs of particular interest:

- No vitreous floaters
- No endophthalmitis
- No retinal detachment
- No implant migration in the anterior chamber
- No retinal vasculitis
- No posterior segment inflammation

- No ocular serious adverse events (SAEs)
- No drug-related systemic SAEs
- No evidence of vorolanib-related ocular or systemic toxicity


- No Durasert-related toxicity or tolerance issues
- No dose limiting toxicity

Ocular AEs observed:

- One eye: mild asymptomatic anterior chamber cell/flare;
 - ▣ treated with Maxitrol® eyedrops – resolved in 8 days – no sequelae or recurrence
- One eye: asymptomatic vitreous hemorrhage from injection; observed

EYP-1901 Phase 1 DAVIO clinical trial demonstrated clinically significant reduction in treatment burden of 75% at 6-months

SOC Anti-VEGF Injections Before and After Treatment




● Anti-VEGF ○ No supplemental injection □ Missed visit ● SOC (Anti-VEGF) + EYP-1901

DAVIO 12-month final data

EYP-1901 Phase 1 DAVIO clinical trial continues clinically significant reduction in treatment burden of 73% at 12-months

SOC Anti-VEGF Injections Before and After Treatment



EYP-1901 Phase 1 DAVIO clinical trial demonstrated that 53% of patients did not require supplemental anti-VEGF treatment at 6-months

Median time to supplemental anti-VEGF: 6 months



EYP-1901 Phase 1 DAVIO clinical trial met all objectives

FAVORABLE SAFETY PROFILE

- No ocular SAEs reported
- No drug-related systemic SAEs reported
- Ocular AEs – majority are mild and expected

POSITIVE EFFICACY & DURABILITY

- Stabilization of mean BCVA and OCT throughout 6 months was achieved
- 53% supplemental anti-VEGF supplement injection free up to 6-months
- 79% reduction in treatment burden at 6-months



**SIX MONTHS MEDIAN
TIME
TO SUPPLEMENTAL ANTI-
VEGF INJECTION**

EYP-1901


**DAVIO PHASE 1 CLINICAL TRIAL
SUBSET ANALYSIS - SUBJECTS WITH NO EXCESS
FLUID AT SCREENING
(N=9)**

DAVIO Phase 1 clinical trial included 9 of 17 (53%) subjects with no "excess fluid" at screening

For 9 eyes at 6 months with no excess fluid at screening

BCVA = +1.2 letters at 5 months
-0.4 letters at 6 months


Mean change in BCVA from screening visit (n = 9)



BCVA: best corrected visual acuity

CST on OCT = +20.8 microns at 5 months
-1.0 microns at 6 months

Mean change in CST from screening visit (n = 9)




OCT: optical coherence tomography; CST: central subfield thickness

DAVIO 12-month final data

DAVIO Phase 1 clinical trial showed a 92% reduction in treatment burden at 6 months among subjects with no "excess fluid" at screening (n=9)

SOC Anti-VEGF Injections Before and After Treatment



DAVIO 12-month final data

Subgroup Analysis: Supplemental Injection-Free Rates Up to Each Visit in Subjects with No Excess Fluid at Screening (n=9)

Median time to supplemental anti-VEGF: 12 months




DAVIO 12-month final data

EYP-1901

TREAT TO MAINTAIN

EYP-1901 demonstrated clinically significant reduction in treatment burden of 75% at 6 Months supporting treat to maintain positioning



TREAT TO MAINTAIN WITH EYP-1901

- About half of eyes in DAVIO could go up to 6 months on EYP-1901 alone
- Another ~30% received only a single supplemental anti-VEGF during 6-months
- About 15 % failed both SoC and 1901 and required multiple supplements

● Anti-VEGF ○ No supplemental injection □ Missed visit ● SOC (Anti-VEGF) + EYP-1901

EYP-1901 positioned as a potential “Treat-to-Maintain” therapy in wet AMD

- *Treat* initially with current anti-VEGF standard of care until VA is maximally improved and retina is as dry as possible (induction phase)
- *Maintain* with EYP-1901 every six months, supplementing if needed with current anti-VEGF biologic
- Based on DAVIO, we believe over half of all wet AMD eyes may be maintained visually and anatomically with EYP-1901 alone
- Another large segment may require occasional supplemental anti-VEGF but a much-reduced interval

EYP-1901

WET AMD PHASE 2 CLINICAL TRIAL (DAVIO 2)

EYP-1901 DAVIO 2 clinical trial is non-pivotal randomized, double-masked, aflibercept controlled



EYP-1901

NPDR PHASE 2 CLINICAL TRIAL (PAVIA)

Diabetic Retinopathy Market


- ✓ Multi billion-dollar opportunity
- ✓ Leading cause of blindness
- ✓ Significant need for longer duration treatment

- Rising prevalence of diabetes
- Growth of the aging population
- Rising awareness by patients
- Rising awareness within healthcare

Diabetic Retinopathy Market Size Report, 2018-2020
(GrandViewResearch.com), Global Diabetic Retinopathy Market Size
Report, Jan. 2022 (MarketDataForecast.com)

26 | HISTORIC DAY 2022

Growing Global DR Market



Analysis includes North America, Europe, Asia Pacific, Latin America, Middle East, and Africa



\$12.27 billion

is the estimated market size by 2032, a result of diabetes prevalence and the aging population

EYEPOINT
PHARMACEUTICALS

EYP-1901 Phase 2 NPDR PAVIA clinical trial is non-pivotal, randomized double-masked, day-one single injection with sham control



YUTIQ® –A sustained delivery treatment of posterior segment uveitis using Durasert



PRODUCTS



Approved for the treatment of posterior segment uveitis



- Commercially launched in U.S. in 2019
- Patent protection to August 2027
- Constant and stable release of flucinolone with Duraser[™] helps prevent uveitis flares for up to 3 years

LICENSE AGREEMENTS

Alimera Sciences, Inc. has rights for non-infectious posterior uveitis in the EMEA

Rights for China, Hong Kong, Taiwan, Macau, Korea and certain SE Asia countries licensed to Ocumenision Therapeutics with a royalty on sales payable to EyePoint

PRODUCTS



Posterior segment uveitis can permanently damage vision with every flare

60K–100K patients are suffering from posterior segment uveitis in the U.S.

The need

- Flares can cause blindness
- 30,000 Americans become blind each year because of uveitis
- Uveitis lasts a lifetime and often affects people in middle age
- Conventional treatment is burdensome for patients and caregivers

The YUTIQ answer


- 3-year continuous treatment in a single injection that controls flares and preserves eyesight
- Single injection in the physician's office
- Gives patients and physicians the confidence that comes with three years of assured compliance

PRODUCTS



Continuous 3-year delivery limits blindness-causing flares

Time to recurrence of uveitis within 36 months




Strong customer demand for YUTIQ continued in Q3 2022

PRODUCTS



**Customer demand is defined as units purchased by Surgery Centers or physicians from the specialty distributors.*



Solid cash position and cash runway beyond anticipated 2023 value inflection points

Balance Sheet – September 30, 2022

- \$157 million of cash and investments
- \$40 million of short and long-term debt
- Cash runway into 2H 2024

Commercial Performance –YTD September 30, 2022

- \$30 million of net product revenues
- Commercial franchise projected to break-even in 2022



EYEPOINT[®]
PHARMACEUTICALS

Investor Presentation

November 2022